For short-half-life peptides that fail the oral feasibility test, long-acting injectable formulations may be the most realistic pathway to reduced treatment burden (Table 4)
[3] Evans M, Lewis ED, Zakaria N, Pelipyagina T, Guthrie N
B., Skreb, F., Cepelak, I., Romic, Z., & Mayer, L
Key medications that slow CKD progression: ACE inhibitors & ARBs cornerstone therapy to reduce proteinuria and protect kidney function SGLT2 inhibitors originally for diabetes, now proven to reduce CKD progression and hospitalizations for heart failure GLP-1 receptor agonists improve glycemic control and show cardiovascular and kidney benefits Non-steroidal MRAs (finerenone) a new option to reduce albuminuria and improve outcomes in diabetic CKD These therapies, when used together and tailored to the patient, represent a modern stack of treatments that can delay or even prevent kidney failure
manual math Use the calculator: Every time you open a new vial with a different concentration When you receive a new prescription with a dose change Anytime the numbers do not feel right or you are second-guessing yourself When teaching someone else to prepare their injection Use manual math: As a verification check on the calculator output When you do not have internet access When you have been on the same concentration and dose for so long that the number is memorized The ideal approach is both
